<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484806</url>
  </required_header>
  <id_info>
    <org_study_id>2017-I2M-3-002</org_study_id>
    <nct_id>NCT03484806</nct_id>
  </id_info>
  <brief_title>Registration and Cohort Study of Valvular Heart Disease in Adults in China</brief_title>
  <acronym>China-VHD</acronym>
  <official_title>China Registry and Cohort Study of Valvular Heart Disease in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational、multicenter, prospective cohort study for adults with significant
      VHD. The purposes of this study were to evaluate the etiology、clinical
      characteristics、treatment modalities, and outcomes of patients with VHD；also to set up
      registration system of adult VHD in China, to build a database of Chinese adult VHD, to
      establish a web-based international standard data acquisition system for VHD and a
      multicenter clinical research platform. The results of the study will provide a basis for the
      future national health policy for prevention and treatment of adult VHD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>2years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Valvular Heart Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients over 60 years old with significant VHD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients over 60 years old meet one of the following conditions.

               1. moderate or above valvular heart disease as defined by echocardiography:
                  （1）aortic stenosis, moderate or above, or valve area ≤1.5cm2, or maximal jet
                  velocity ≥3.0m/sec, or mean pressure gradient ≥20mmHg, （2）aortic regurgitation,
                  moderate or above, or jet width ≥25% of left ventricular outflow tract, or
                  regurgitant volume ≥30ml/beat, or regurgitant fraction ≥30%, （3）mitral stenosis,
                  moderate or above, or valve area ≤1.5cm2, （4）mitral regurgitation, moderate or
                  above, or effective regurgitant orifice ≥0.2cm2, or regurgitant volume
                  ≥30ml/beat, or regurgitant fraction ≥30%, （5）tricuspid stenosis, moderate or
                  above, or valve area ≤1.0cm2, （6）tricuspid regurgitation, moderate or above, or
                  central jet area ≥5.0cm2, （7）pulmonic stenosis, moderate or above, or maximal jet
                  velocity &gt;4m/sec, （8）pulmonic regurgitation, moderate or above,

               2. or patients who had undergone any operation on a cardiac valve (percutaneous
                  balloon commissurotomy, valve repair, valve replacement, transcatheter aortic
                  valve implantation),

               3. or diagnosis of endocarditis as assessed by Duke criteria.

        Exclusion Criteria:

          -  Patients cannot be followed up for any reasons. Patients have been enrolled in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>haiyan xu, doctor</last_name>
    <phone>+86 13681012249</phone>
    <email>xuhaiyan@fuwaihospital.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yunqing ye, master</last_name>
    <phone>+86 13699282532</phone>
    <email>judia8510@163.com</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China National Center for Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Yongjian Wu</investigator_full_name>
    <investigator_title>coronary heart disease center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

